Marion Merrell Dow’s Targocid (teicoplanin)
Executive Summary
FDA's Anti-Infective Drugs Advisory Committee reviewed data from MMD's NDA for the injectable antibiotic treatment for gram- positive infections in closed session on Jan. 28. The committee requested that the company provide additional data to supplement its NDA, which was submitted in March 1991. MMD has said that FDA is giving Targocid a priority review.